ceftaroline + vancomycin

Ceftaroline + vancomycin is a combination of two intravenous antibiotics used primarily as salvage therapy for persistent or complicated methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Ceftaroline is a fifth-generation cephalosporin with activity against MRSA, acting by binding to penicillin-binding proteins and inhibiting bacterial cell wall synthesis. Vancomycin is a glycopeptide antibiotic that inhibits cell wall biosynthesis in Gram-positive bacteria by binding to D-alanyl-D-alanine termini of cell wall precursors, preventing peptidoglycan polymerization. The combination has been explored for synergy in cases where monotherapy fails, particularly in severe or persistent MRSA infections[1][10][7]. While some studies suggest rapid clearance of bacteremia and high microbiological cure rates with this regimen, clinical outcomes such as mortality and recurrence are not consistently superior to monotherapy[1][10]. Both drugs are administered intravenously and require monitoring for adverse effects such as nephrotoxicity (vancomycin) and rash or neutropenia (ceftaroline)[10].